Rexulti® Compulsive Behavior Lawsuits
Rexulti® (brexpiprazole) is a prescription drug approved to treat major depressive disorder and schizophrenia. Approved by the U.S. Food and Drug Administration in 2015, the medication is developed by Otsuka Pharmaceutical, the makers of the top-selling antipsychotic drug Abilify®. However, the two drugs may have more than just a manufacturer in common. Similar to Abilify, taking Rexulti may increase the likelihood of compulsive behaviors, such as pathological gambling and hypersexuality.
At Ferrer, Poirot & Wansbrough, our nationwide drug injury attorneys understand that patients who have taken Rexulti may face severe consequences in their personal and professional lives. If you or someone you love took Rexulti and experienced poor impulse control, including behaviors such as compulsive gambling or hypersexual activity, we want to help. Dial (800) 210-8503 or complete our free online form to get help 24 hours a day, 7 days a week.
Rexulti® Patients May Face Impulse Control Disorders
Impulse control disorders, such as pathological gambling and hypersexuality, have been reported in other antipsychotic drugs that work in a similar way, such as Abilify. If you or a loved one experienced compulsive behaviors after taking Rexulti, you may be entitled to compensation for:
- Damaged reputation
- Emotional distress
- Financial losses
- Gambling losses
- Medical fees
- Punitive damages
Get Experienced Help With Your Rexulti® Lawsuit
At Ferrer, Poirot & Wansbrough, our attorneys have been helping injury victims for more than 35 years. You can count on our legal team to provide the knowledge and resources necessary to help maximize results. No matter where you live, our national legal team wants to provide the experienced representation you deserve. Call (800) 210-8503 or contact us online to discuss your Rexulti claim anytime.
Rexulti® is a registered trademark of Lundbeck and Otsuka America Pharmaceutical, and is used here only to identify the product in question.
This law firm is not associated with, sponsored by, or affiliated with Lundbeck; Otsuka Pharmaceutical Co., Ltd.; or the U.S. Food and Drug Administration.